JP2012532195A - 乳オリゴ糖による炎症の阻害 - Google Patents

乳オリゴ糖による炎症の阻害 Download PDF

Info

Publication number
JP2012532195A
JP2012532195A JP2012519618A JP2012519618A JP2012532195A JP 2012532195 A JP2012532195 A JP 2012532195A JP 2012519618 A JP2012519618 A JP 2012519618A JP 2012519618 A JP2012519618 A JP 2012519618A JP 2012532195 A JP2012532195 A JP 2012532195A
Authority
JP
Japan
Prior art keywords
milk
oligosaccharide
lacto
reducing end
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012519618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532195A5 (enExample
Inventor
アーディス エル． モロウ，
デービッド エス． ニューバーグ，
ギレルモ エム． ルイズ−パラシオス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43429494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012532195(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of JP2012532195A publication Critical patent/JP2012532195A/ja
Publication of JP2012532195A5 publication Critical patent/JP2012532195A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pediatric Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2012519618A 2009-07-06 2010-07-02 乳オリゴ糖による炎症の阻害 Pending JP2012532195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22314509P 2009-07-06 2009-07-06
US61/223,145 2009-07-06
PCT/US2010/040895 WO2011005681A1 (en) 2009-07-06 2010-07-02 Inhibiting inflammation with milk oligosaccharides

Publications (2)

Publication Number Publication Date
JP2012532195A true JP2012532195A (ja) 2012-12-13
JP2012532195A5 JP2012532195A5 (enExample) 2013-08-15

Family

ID=43429494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519618A Pending JP2012532195A (ja) 2009-07-06 2010-07-02 乳オリゴ糖による炎症の阻害

Country Status (7)

Country Link
US (5) US9034847B2 (enExample)
EP (2) EP3248605A1 (enExample)
JP (1) JP2012532195A (enExample)
CA (1) CA2767043C (enExample)
DK (1) DK2451462T3 (enExample)
ES (1) ES2651067T3 (enExample)
WO (1) WO2011005681A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533915A (ja) * 2014-10-29 2017-11-16 グリコム・アクティーゼルスカブＧｌｙｃｏｍ Ａ／Ｓ 過敏性腸症候群の治療のための合成組成物および方法
JP2019115349A (ja) * 2014-09-09 2019-07-18 グリコシン リミテッド ライアビリティー カンパニー フコシル化オリゴ糖の生産において使用するためのα（１，３）フコシルトランスフェラーゼ
JP2020513014A (ja) * 2017-04-07 2020-04-30 チルドレンズ ホスピタル メディカル センター ２’−フコシルラクトース化合物による炎症性腸疾患の治療
JP2021504420A (ja) * 2017-11-30 2021-02-15 グリコム・アクティーゼルスカブＧｌｙｃｏｍ Ａ／Ｓ 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物
JP2024504983A (ja) * 2021-01-22 2024-02-02 プロラクタ バイオサイエンス，インコーポレイテッド ヒト乳局所製剤
US11896605B2 (en) 2014-10-29 2024-02-13 Glycom A/S Composition comprising HMSs/HMOs and use thereof

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033011A1 (en) 2007-09-07 2009-03-12 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
CN103025749B (zh) 2010-06-01 2016-06-01 格礼卡姆股份公司 2’-o-岩藻糖基乳糖的多晶型物及其制备
NZ612455A (en) 2010-12-31 2015-02-27 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
BR112013016587A2 (pt) 2010-12-31 2016-09-27 Abbott Lab formulações nutricionais incluindo oligossacarídeos de leite humano e antioxidantes e usos das mesmas
EP3510873A1 (en) 2010-12-31 2019-07-17 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CN110051676A (zh) 2010-12-31 2019-07-26 雅培制药有限公司 用于调节炎症的人乳寡糖
SG10202110501RA (en) 2010-12-31 2021-11-29 Abbott Lab Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides
ES2708924T3 (es) 2010-12-31 2019-04-12 Abbott Lab Procedimientos de uso de oligosacáridos de la leche humana para mejorar la salud respiratoria de las vías respiratorias
WO2012092159A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
PH12013501481A1 (en) 2011-02-04 2013-08-28 Univ California Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
BR112014001472A2 (pt) 2011-07-22 2017-02-21 Abbott Lab galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
BR112014004772A2 (pt) * 2011-08-29 2017-03-21 Abbott Lab oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal
US20150265661A1 (en) * 2012-04-13 2015-09-24 Trustees Of Boston College Prebiotic effect of sialyllactose
EP2708147B1 (en) 2012-09-14 2020-03-11 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
ES2572831T3 (es) * 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
CA2894897C (en) * 2012-12-20 2018-09-18 Abbott Laboratories Nutritional formulations using human milk oligosaccharides for modulating inflammation
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) * 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
DK2896628T3 (en) 2014-01-20 2019-01-14 Jennewein Biotechnologie Gmbh Process for Effective Purification of Neutral Milk Oligosaccharides (HMOs) from Microbial Fermentation
EP3129030A1 (en) 2014-04-08 2017-02-15 Abbott Laboratories Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
PL3212198T3 (pl) * 2014-10-29 2021-08-23 Glycom A/S Syntetyczna kompozycja i sposób promowania gojenia się błony śluzowej
US10709721B2 (en) * 2015-03-05 2020-07-14 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
WO2016176484A1 (en) * 2015-04-28 2016-11-03 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
JP2018532696A (ja) * 2015-08-25 2018-11-08 カレイド・バイオサイエンシズ・インコーポレイテッド グリカン組成物およびその使用
PL3368046T3 (pl) 2015-10-28 2022-11-28 Glycom A/S Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania
RU2019105567A (ru) 2016-07-28 2020-08-28 Фонтерра Ко-Оперэйтив Груп Лимитед Молочный продукт и способ
CN116850198A (zh) 2017-01-23 2023-10-10 库比奥尼有限公司 一种含有唾液酸乳糖或其盐作为有效成分的用于预防或治疗退行性关节炎的组合物
EP3691658A4 (en) * 2017-10-04 2021-06-23 The Regents of The University of California IMMUNOMODULATOR OLIGOSACCHARIDES
ES2987964T3 (es) * 2017-11-30 2024-11-18 Glycom As Mezcla de HMO para tratar la sensibilidad al trigo
US11304966B2 (en) 2017-12-22 2022-04-19 Glycom A/S Composition comprising HMOs for preventing or reducing nociception
SG11202011817WA (en) * 2018-06-01 2020-12-30 Evolve Biosystems Inc Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires
BR112021011071A2 (pt) 2018-12-19 2021-08-31 Glycom A/S Composição e método para o tratamento de seres humanos utilizando dietas com baixo teor de fodmap
US20220054515A1 (en) * 2018-12-21 2022-02-24 Glycom A/S Composition and method for promoting intestinal barrier healing
WO2020210027A1 (en) 2019-04-09 2020-10-15 Lupa Bio, Inc. Immunomodulatory oligosaccharides for the treatment of pain
CN110038020A (zh) * 2019-04-23 2019-07-23 河南省农业科学院 唾液酸模拟物在制备抑制巨噬细胞感染或激活状态下所引起炎症的药物中的应用
MX2022002949A (es) 2019-09-24 2022-04-06 Prolacta Bioscience Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.
US11712445B2 (en) * 2021-04-30 2023-08-01 Sourabh Kharait Compositions and methods for improving gastrointestinal function in subjects with renal disease
US20250000884A1 (en) * 2021-10-04 2025-01-02 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods of use thereof for treating inflammatory lung diseases
WO2024218196A1 (en) * 2023-04-19 2024-10-24 Chr. Hansen A/S 3-fucosyllactose

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087468A2 (en) * 2006-01-09 2007-08-02 Children's Hospital Medical Center Adiponectin for treatment of various disorders

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1246902A (en) 1969-03-27 1971-09-22 Boots Pure Drug Co Ltd Improvements in therapeutic agents
DK455088D0 (da) 1988-08-12 1988-08-12 Symbicom Ab Syntetiske receptoranaloger
US5874261A (en) 1988-09-02 1999-02-23 The Trustees Of The University Of Pennsylvania Method for the purification of glycosyltransferases
AU1926692A (en) 1991-04-19 1992-11-17 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for endothelial binding
JPH07509139A (ja) 1992-07-30 1995-10-12 インターナショナル　フラワー　ディベロップメンツ　プロプライアタリー　リミティド グリコシルトランスフェラーゼ酵素をコードする遺伝子配列およびその用途
US5874271A (en) 1992-08-21 1999-02-23 Takara Shuzo Co., Ltd. Human glycosyltransferase gene, compounds and method for inhibiting cancerous metastasis
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
CN1121311A (zh) * 1993-02-26 1996-04-24 扬·施塔芬·诺马克 应用低聚糖苷作为细菌粘连的抑制剂
US5484773A (en) 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
JPH09509165A (ja) 1994-02-16 1997-09-16 ファーミング ベスローテン フェンノートシャップ ミルクからのラクトフェリンの分離
AU692841B2 (en) 1994-03-09 1998-06-18 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US5750176A (en) 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
WO1995034663A1 (en) 1994-06-13 1995-12-21 Banyu Pharmaceutical Co., Ltd. Gene coding for glycosyltransferase and use thereof
US5576300A (en) 1994-09-16 1996-11-19 Abbott Laboratories Method for inhibition of human rotavirus infection
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5858752A (en) 1995-06-07 1999-01-12 The General Hospital Corporation Fucosyltransferase genes and uses thereof
JP2758856B2 (ja) 1995-06-15 1998-05-28 理化学研究所 セラミドグルコシルトランスフェラーゼ
US6054304A (en) 1996-01-24 2000-04-25 Toyo Boseki Kabushiki Kaisha α1-6 fucosyltransferase
US6841543B1 (en) * 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US5856159A (en) 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US5821097A (en) 1996-09-13 1998-10-13 Eli Lilly And Company Glycosyltransferase gene GtfC from Amycolatopsis orientalis
US5821098A (en) 1996-09-13 1998-10-13 Eli Lilly And Company Glycosyltransferase gene gtfD from amycolatopsis orientalis
US5821100A (en) 1996-09-13 1998-10-13 Eli Lilly And Company Glycosyltransferase gene gtfb from Amycolatopsis orientalis
US5871983A (en) 1996-09-13 1999-02-16 Eli Lilly And Company Glucosyltransferase gene GTFE from amycolatopsis orientalis
CA2664150C (en) 1996-09-17 2013-01-08 Kyowa Hakko Bio Co., Ltd. Processes for producing sugar nucleotides and complex carbohydrates
US5922540A (en) 1996-12-20 1999-07-13 Eli Lilly And Company Monofunctional glycosyltransferase gene of Staphylococcus aureus
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
US6132710A (en) 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US6087143A (en) 1997-09-05 2000-07-11 Eli Lilly And Company Glycosyltransferase gene gtfA from Amycolatopsis orientalis
US7244601B2 (en) 1997-12-15 2007-07-17 National Research Council Of Canada Fusion proteins for use in enzymatic synthesis of oligosaccharides
US5955282A (en) 1998-04-03 1999-09-21 Incyte Pharmaceuticals, Inc. Human galactosyltransferases
US6126961A (en) 1998-04-13 2000-10-03 Kross; Robert D. Composition and method for reducing the colonization of animal intestines by salmonella and other bacterial pathogens
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6238894B1 (en) 1998-11-04 2001-05-29 Diane Taylor α1,2 fucosyltransferase
US6291435B1 (en) 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
US20030036070A1 (en) 1999-10-21 2003-02-20 Shukti Chakravarti Gene expression profiling of inflammatory bowel disease
WO2002018556A2 (en) 2000-08-31 2002-03-07 Millennium Pharmaceuticals, Inc. 8797, a human galactosyltransferase and uses thereof
FI109811B (fi) 2000-09-26 2002-10-15 Medicel Oy Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
AU2002239560B2 (en) 2000-11-28 2006-03-02 Premacure Ab Determination of risk and treatment of complications of prematurity
FI20021989A0 (fi) 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
NZ546664A (en) 2003-10-24 2009-04-30 Nutricia Nv Synbiotic composition for infants
CA2548140A1 (en) 2003-12-05 2005-06-23 University Of Massachusetts Oligosaccharide compositions and use thereof in the treatment of infection
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US20090169535A1 (en) 2004-07-27 2009-07-02 The Regents Of The University Of California Treatment of epilepsy by expressing st3gal-iii
BRPI0513639A (pt) 2004-08-06 2008-05-13 Genentech Inc métodos de previsão da sensibilidade, métodos de indução da apoptose e métodos de tratamento de disfunção em mamìferos e de cáncer
PL2805625T5 (pl) 2005-02-28 2023-03-13 N.V. Nutricia Kompozycja odżywcza z prebiotykami i probiotykami
EP1888789A2 (en) 2005-06-06 2008-02-20 Wyeth a Corporation of the State of Delaware Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
RU2430631C2 (ru) 2006-02-10 2011-10-10 Нестек С.А. Пребиотическая смесь олигосахаридов и пищевой продукт, ее содержащий
JP2009532372A (ja) 2006-03-31 2009-09-10 ウェルスタット セラピューティクス コーポレイション 代謝障害の併用治療
US8197872B2 (en) * 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2009033011A1 (en) 2007-09-07 2009-03-12 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
CN102300575A (zh) 2008-12-02 2011-12-28 普罗莱克塔生物科学公司 人乳渗透物组合物及其制备和使用方法
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
ES2680920T3 (es) 2010-07-12 2018-09-11 The Regents Of The University Of California Oligosacáridos de leche bovina
JP6129821B2 (ja) 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
WO2013057049A1 (en) 2011-10-18 2013-04-25 Nestec S.A. Composition for use in brain growth and/or cognitive and/or psychomotor development
MX354727B (es) 2011-10-18 2018-03-16 Nestec Sa Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio.
BR112014008425A2 (pt) 2011-10-18 2017-04-11 Nestec Sa composição para o uso na promoção de angiogênese intestinal e de absorção de nutriente e de tolerância a alimentação enteral e/ou na prevenção e/ou no tratamento de inflamação intestinal e/ou na recuperação após a lesão e a cirurgia intestinal
US20150265661A1 (en) 2012-04-13 2015-09-24 Trustees Of Boston College Prebiotic effect of sialyllactose
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
WO2016176484A1 (en) 2015-04-28 2016-11-03 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
EP3349763B1 (en) 2015-09-14 2021-08-11 Glycom A/S Composition for use in microbiota modulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087468A2 (en) * 2006-01-09 2007-08-02 Children's Hospital Medical Center Adiponectin for treatment of various disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014029441; ＤＡＤＤＡＯＵＡ，　Ａ．　ｅｔ　ａｌ．: Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｎｕｔｒｉｔｉｏｎ Ｖｏｌ．１６３, 2006, ｐ．６７２-６７６ *
JPN6014029442; ＣＨＡＴＵＲＶＥＤＩ，　Ｐ．　ｅｔ　ａｌ．: Ａｎａｌｉｔｉｃａｌ　Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２５１, 1997, ｐ．８９-９７ *
JPN6014029444; ＢＯＤＥ，　Ｌ．　ｅｔ　ａｌ．: Ｔｈｒｏｍｂ　Ｈａｅｍｏｓｔ Ｖｏｌ．９２, 2004, ｐ．１４０２-１４１０ *
JPN6015014883; Ｇｌｙｃｏｃｏｎｊｕｇａｔｅ　Ｊｏｕｒｎａｌ Ｖｏｌ．１８, 2001, ｐ．３５７-３７１ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019115349A (ja) * 2014-09-09 2019-07-18 グリコシン リミテッド ライアビリティー カンパニー フコシル化オリゴ糖の生産において使用するためのα（１，３）フコシルトランスフェラーゼ
JP2022023166A (ja) * 2014-09-09 2022-02-07 グリコシン リミテッド ライアビリティー カンパニー フコシル化オリゴ糖の生産において使用するためのα（１，３）フコシルトランスフェラーゼ
US11453900B2 (en) 2014-09-09 2022-09-27 Glycosyn LLC Alpha (1,3) fucosyltransferases for use in the production of fucosylated oligosaccharides
JP2017533915A (ja) * 2014-10-29 2017-11-16 グリコム・アクティーゼルスカブＧｌｙｃｏｍ Ａ／Ｓ 過敏性腸症候群の治療のための合成組成物および方法
JP7182872B2 (ja) 2014-10-29 2022-12-05 グリコム・アクティーゼルスカブ 過敏性腸症候群の治療のための合成組成物および方法
US11833165B2 (en) 2014-10-29 2023-12-05 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US11896605B2 (en) 2014-10-29 2024-02-13 Glycom A/S Composition comprising HMSs/HMOs and use thereof
JP2020513014A (ja) * 2017-04-07 2020-04-30 チルドレンズ ホスピタル メディカル センター ２’−フコシルラクトース化合物による炎症性腸疾患の治療
JP2021504420A (ja) * 2017-11-30 2021-02-15 グリコム・アクティーゼルスカブＧｌｙｃｏｍ Ａ／Ｓ 微生物叢調節のためのヒトミルクオリゴ糖およびその合成組成物
JP2024504983A (ja) * 2021-01-22 2024-02-02 プロラクタ バイオサイエンス，インコーポレイテッド ヒト乳局所製剤

Also Published As

Publication number Publication date
EP2451462A4 (en) 2012-12-12
US11324765B2 (en) 2022-05-10
US20230101412A1 (en) 2023-03-30
WO2011005681A1 (en) 2011-01-13
EP2451462B1 (en) 2017-09-06
US20120202753A1 (en) 2012-08-09
CA2767043C (en) 2020-07-14
ES2651067T3 (es) 2018-01-24
US11058697B2 (en) 2021-07-13
DK2451462T3 (en) 2017-12-11
CA2767043A1 (en) 2011-01-13
US20150306120A1 (en) 2015-10-29
WO2011005681A8 (en) 2011-08-04
US20190099435A1 (en) 2019-04-04
US9034847B2 (en) 2015-05-19
EP2451462A1 (en) 2012-05-16
EP3248605A1 (en) 2017-11-29
US10098903B2 (en) 2018-10-16
US12171773B2 (en) 2024-12-24
US20210283155A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US12171773B2 (en) Inhibiting inflammation with milk oligosaccharides
Newburg Glycobiology of human milk
RU2511044C2 (ru) ПОЛИСАХАРИД ИЗ ШТАММА Bifidobacterium infantis И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ.
JP2012532195A5 (enExample)
Xu et al. Eucheuma cottonii sulfated oligosaccharides decrease food allergic responses in animal models by up-regulating regulatory T (Treg) cells
JP6139562B2 (ja) 成長因子、サイトカイン、抗菌／抗ウイルス因子、幹細胞刺激因子、補体タンパク質ｃ３ａ／ｃ４ａ、免疫グロブリンおよび走化性因子の組合せ
WO2021185874A1 (en) Use of lactoferrin
EP3917575A1 (en) Phlip®-mediated carbohydrate tethering at cell surfaces to induce immune response
US9730969B2 (en) Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
SK8152002A3 (en) Novel helicobacter pylori-binding substances and use thereof
Lacomba et al. Effect of simulated gastrointestinal digestion on sialic acid and gangliosides present in human milk and infant formulas
JP2006070217A (ja) オウギ属植物地上部由来の多糖および生体防御機能賦活化剤
WO2015007326A1 (en) Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases
Wu et al. Diverse domains of raspberry pectin: critical determinants for protecting against IBDs
JP2012051830A (ja) 胃粘膜保護剤
AU2015225727A1 (en) Nutritional compositions containing ceramide
CN103930116A (zh) 治疗慢性鼻及鼻窦炎的脂质缀合物
HOsPitsl Morrow et al.(43) Pub. Date: Aug. 9, 2012
JP6178162B2 (ja) β−ガラクトシダーゼで処理されたムチンを含むマクロファージ活性化剤
Osimanjiang Glycosylation and Sexual Dimorphism in Spinal Cord Injury
Capitán Cañadas New insights into the mechanisms of prebiotics and microbiota on intestinal defense
GB2608587A (en) Use of extensively hydrolysed protein
HK1076735A1 (zh) 抗原特异性ige抗体产生抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150415